For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Enfuvirtide
Illustration for Enfuvirtide

THE PEPSRADAR ENCYCLOPEDIA

Enfuvirtide

Combination antiretroviral treatment

Clinical medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Enfuvirtide · KEY FACTS

Content updated · how dates work

Saved peptides

What is Enfuvirtide?

Enfuvirtide is an HIV fusion inhibitor with historical combination-treatment evidence. MedlinePlus reports that the injection has been discontinued in the United States.

Biological role or research focus

Combination antiretroviral treatment.

The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.

Role reference: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

Names you may encounter

T-20

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
HIV fusion-inhibitor peptide
Research focus
Combination antiretroviral treatment
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

Quick answers

Is Enfuvirtide FDA approved?
It was approved but is no longer marketed. Fuzeon (NDA 021481, approved 2003) for HIV-1 infection; Drugs@FDA now lists it as discontinued (no longer marketed, not a safety withdrawal finding). Source ↗
Is Enfuvirtide safe?
Enfuvirtide (Fuzeon), an injected HIV fusion inhibitor now discontinued in the US, caused injection-site reactions in nearly all users; its label also warns of pneumonia and allergic reactions. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Enfuvirtide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
TORO-1 (2003)Human randomized trial501 people with HIV and substantial prior antiretroviral treatment or resistance.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2003

TORO-1

Did adding enfuvirtide improve viral-load and CD4 outcomes?

Population / model
501 people with HIV and substantial prior antiretroviral treatment or resistance.
Study design
Randomized open-label comparison of enfuvirtide plus optimized background therapy with optimized background therapy alone; 24-week analysis.
Main finding
Viral load fell by 1.696 versus 0.764 log10 copies per milliliter. CD4 counts increased by 76 versus 32 cells per cubic millimeter.
Limits & context
The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.

Source: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

41 registered studies name Enfuvirtide as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 34 completed and 7 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)
NCT00302822 · French National Agency for Research on AIDS and Viral Hepatitis
CompletedPhase 32006-04195
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
NCT00120367 · French National Agency for Research on AIDS and Viral Hepatitis
CompletedPhase 22005-0430
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
NCT01836068 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CompletedEarly phase 12013-0611
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
NCT00537394 · National Institute of Allergy and Infectious Diseases (NIAID)
CompletedPhase 32008-01517
Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
NCT00001118 · National Institute of Allergy and Infectious Diseases (NIAID)
CompletedPhase 124
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
NCT00051831 · National Institute of Allergy and Infectious Diseases (NIAID)
CompletedNot applicable2003-1019
Adding New Drugs for HIV Infected Patients Failing Current Therapy
NCT00031044 · National Institute of Allergy and Infectious Diseases (NIAID)
CompletedPhase 1 / Phase 250
A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
NCT00344760 · University of Maryland, Baltimore
CompletedPhase 42005-012

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 41 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Enfuvirtide. ↗
Drugs · 2003 · Journal Article, Review

Enfuvirtide. ↗
· 2012 · Review

Enfuvirtide. ↗
Expert opinion on investigational drugs · 2002 Dec · Journal Article, Review

Enfuvirtide. ↗
Nature reviews. Drug discovery · 2003 May · Journal Article

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Enfuvirtide (Fuzeon), an injected HIV fusion inhibitor now discontinued in the US, caused injection-site reactions in nearly all users; its label also warns of pneumonia and allergic reactions.

Human safety data: FDA label

An FDA label exists (last revised 2019), and Drugs@FDA lists Fuzeon as discontinued. In phase 3 trials almost all users had injection-site reactions. It has not been studied in people without HIV.

Take extra care with: Blood thinners or bleeding problemsPregnancy or breastfeeding

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • Allergy to enfuvirtide or any ingredient
  • Breastfeeding: not recommended because of the risk of passing on HIV

Interactions

  • Blood thinners, or bleeding disorders such as hemophilia: higher risk of bleeding after injection
  • Ritonavir, saquinavir/ritonavir and rifampin: studied, with no meaningful change in enfuvirtide levels

Serious risks

  • Higher rate of bacterial pneumonia in trials
  • Whole-body allergic reactions that may return if the drug is restarted
  • Immune reconstitution syndrome, including autoimmune disorders
  • Skin infection (cellulitis) at injection sites
  • Nerve pain, bruising and blood pooling with a needle-free injector device
  • Possible false-positive HIV antibody test in people without HIV

Common side effects

  • injection-site reactions (pain, redness, hard lumps, bruising)
  • diarrhea
  • nausea
  • fatigue

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Fuzeon (enfuvirtide) prescribing information, 2019 ↗ · Drugs@FDA: Fuzeon, NDA 021481 (discontinued) ↗ · Lalezari et al., NEJM 2003: TORO 1 phase 3 trial of enfuvirtide ↗

What the featured evidence can tell us

Injection-site reactions occurred in 98% of enfuvirtide recipients. Pneumonia was reported more frequently in the enfuvirtide group. Specialist combination-treatment decisions require complete medicine information.

Source: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

Identity, route, and evidence limits

The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.

Source: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

Official product context · checked October 4, 2026

The linked medication monograph is archived in the sense that it is no longer being updated following U.S. discontinuation. Historical safety information and trial preparations are not substitutes for current local product labeling.

Source: MedlinePlus · Enfuvirtide · U.S. discontinuation notice ↗

Regulatory status

U.S. FDA approval
Approved, now discontinued
Fuzeon (NDA 021481, approved 2003) for HIV-1 infection; Drugs@FDA now lists it as discontinued (no longer marketed, not a safety withdrawal finding). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Medicine status & clinical context

MedlinePlus now states that enfuvirtide injection has been discontinued in the United States and that its monograph is no longer updated. Historical HIV trial results remain relevant to the evidence record, but should not be read as evidence of current U.S. availability. For other countries, consult current local product information.

The selected study evaluates combination HIV treatment in a treatment-experienced population. It does not establish standalone treatment, general infection prevention, or a consumer immune-support use.

Source: MedlinePlus · Enfuvirtide · U.S. discontinuation notice ↗

Source: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.

No verified matching catalog listing yet

We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.

How Enfuvirtide works

It interferes with HIV fusion through the viral entry machinery. Antiviral activity against a specific virus is different from a nonspecific “immune boost.”

Source: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

Molecular structure

Enfuvirtide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16130199 ↗

Questions worth asking

  • Is enfuvirtide a general immune-enhancement peptide?
  • What population, comparator, and route were actually studied?
  • The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Is enfuvirtide a general immune-enhancement peptide?

No. Its mechanism and trial concern HIV entry inhibition within a specialist antiretroviral regimen.

Source: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

Does this page establish a supplier’s product quality?

No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.

Source: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗

Is enfuvirtide currently available in the United States?

No. MedlinePlus reports U.S. discontinuation; availability elsewhere requires current local product information.

Source: MedlinePlus · Enfuvirtide · U.S. discontinuation notice ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Enfuvirtide

Download illustration ↓Source record ↗
Enfuvirtide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.